Kodiak Sciences INC

Kodiak Sciences Inc. successfully concluded its 2026 Annual Meeting of Stockholders with all director nominees elected and executive compensation approved.

Kodiak Sciences announced positive Phase 3 GLOW2 results for Zenkuda, advancing toward a multi-indication BLA submission, alongside progress in other late-stage programs and first-quarter 2026 financial results.

Kodiak Sciences announced positive Phase 3 GLOW2 study results for Zenkuda in diabetic retinopathy, alongside advancing multiple late-stage programs and reporting Q4 and full-year 2025 financial results.

Kodiak Sciences announced positive topline results from its GLOW2 Phase 3 study, demonstrating Zenkuda's superiority over sham in diabetic retinopathy treatment.

Kodiak Sciences Inc. completed a public offering of 8 million common shares, raising approximately $184 million in gross proceeds.

Kodiak Sciences Inc. reported its third-quarter 2025 financial results and highlighted significant progress across its late-stage clinical programs for retinal diseases.

Kodiak Sciences reported substantial net losses and negative cash flows, raising significant doubt about its ability to continue as a going concern, despite ongoing clinical trial progress for its retinal disease therapies.

Kodiak Sciences reported increased net losses and substantial doubt about its ability to continue as a going concern, despite ongoing progress in its late-stage retinal disease clinical programs.

Kodiak Sciences reports a net loss of $57.5 million for Q1 2025 and provides updates on its tarcocimab, KSI-501, and KSI-101 clinical programs.

Kodiak Sciences reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and advancements in its pipeline.

Kodiak Sciences reported its second quarter 2024 financial results, highlighting progress in its clinical programs and leadership changes.

Kodiak Sciences reported a net loss of $43.0 million for the first quarter of 2024, while advancing its clinical programs and manufacturing capabilities.

Kodiak Sciences reports significant clinical trial advancements for its retinal disease pipeline, including successful Phase 3 studies for Zenkuda, alongside substantial net losses and going concern doubt.

Kodiak Sciences announces its 2024 financial results and provides updates on its clinical programs targeting retinal diseases, including tarcocimab, KSI-501, and KSI-101.

Kodiak Sciences reports positive results from key clinical trials and progress in manufacturing, while also detailing financial performance for the year ended December 31, 2023.

John A. Borgeson, Chief Financial Officer of Kodiak Sciences Inc., received 66,500 shares of common stock on July 15, 2026.

Victor Perlroth, Chairman and CEO, a Director and 10% owner of Kodiak Sciences Inc., received 100,000 shares of common stock on July 15, 2026.

Kodiak Sciences Inc. reports that Director Taiyin Yang acquired stock options under a Rule 10b5-1(c) plan.

Kodiak Sciences Inc. reports a Form 4 filing detailing stock option grants to Director Robert Profusek.

Kodiak Sciences Inc. reports that Director Richard S. Levy was granted stock options for 17,731 shares of common stock.

Kodiak Sciences Inc. reports that Director Bassil Dahiyat acquired stock options, with vesting contingent on continued service.

Kodiak Sciences Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 2, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Kodiak Sciences Inc. will hold its 2025 Annual Meeting of Stockholders on June 2, 2025, featuring proposals for director elections, executive compensation approval, and auditor ratification.

Kodiak Sciences announces its 2025 Annual Meeting of Stockholders to be held virtually on June 2, 2025, detailing proposals for director elections, executive compensation, and auditor ratification.

Kodiak Sciences Inc. will hold its 2024 Annual Meeting of Stockholders on June 4, 2024, to elect directors, approve executive compensation, and ratify the appointment of PricewaterhouseCoopers LLP as the independent auditor.

Kodiak Sciences will hold its 2024 Annual Meeting of Stockholders virtually on June 4, 2024, to vote on director elections, executive compensation, and the ratification of its independent accounting firm.

Baker Bros. Advisors and its affiliates increased their beneficial ownership in Kodiak Sciences Inc. to 32.8% following participation in a recent public offering.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 5.7% of Kodiak Sciences Inc. common stock.

Point72 Asset Management and Steven A. Cohen have reported a 1% beneficial ownership stake in Kodiak Sciences Inc. via a Schedule 13G filing.

Point72 Asset Management, along with affiliates and Steven A. Cohen, has disclosed a 5.5% beneficial ownership stake in Kodiak Sciences Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.4% passive beneficial ownership stake in Kodiak Sciences Inc. as of March 31, 2025.

Dr. D. Victor Perlroth has filed an amended Schedule 13G, reporting beneficial ownership of 11.0% of Kodiak Sciences Inc.'s common stock as of December 31, 2024.